WuXi AppTec Q1 Revenue +28.8%, Shares +15%

WuXi AppTec reported Q1 revenue of 12.44 bn yuan, up 28.8% YoY, and net profit of 4.65 bn yuan, up 26.7%.
Chemistry segment revenue surged 43.7%, driven by small‑molecule development and manufacturing expansion.
Testing and biology segments grew 27.4% and 10.1% respectively, aided by demand for nucleic acids and peptides.
Hong Kong‑listed shares jumped 15% to HK$144.8, their highest level since December 2021.